jueves, 16 de agosto de 2012
WHO Pharmaceuticals Newsletter No. 4, 2012
Contenido
Regulatory Matters
Calcitonin- containing medicines ..................................................................... 4
Candesartan ................................................................................................ 4
Dabigatran etexilate ..................................................................................... 5
Dalfampridine .............................................................................................. 5
Denosumab ................................................................................................. 5
Doripenem .................................................................................................. 6
Febuxostat .................................................................................................. 6
Tolperisone ................................................................................................. 6
Trimetazidine-containing medicines ................................................................ 7
Hepatitis B Immune Globulin (Human) Injection ............................................... 8
Immune Globulin Intravenous (Human) ........................................................... 8
Oral tacrolimus ............................................................................................ 8
Safety of medicines
Bisphosphonates, corticosteroids, angiogenesis inhibitors and
denosumab ................................................................................................ 10
Butterbur ................................................................................................... 10
Caffeine citrate ........................................................................................... 10
Non-steroidal anti-inflammatory drugs....................................................... 10
Peanut Oil .................................................................................................. 11
Serotonergic medicines ................................................................................ 11
Statins and ciclosporin ................................................................................. 12
Tacrolimus ointment .................................................................................... 12
Zolpidem ................................................................................................... 12
Signal
Dronedarone, hyperthyroidism and decreased Thyroid Stimulating
Hormone.................................................................................................... 14
Mometasone and Arrhythmia ........................................................................ 20
Feature
Paediatric morphine dosages......................................................................... 26
Ninth meeting of the WHO Advisory Committee on Safety of Medicinal
Products (ACSoMP) ...................................................................................... 29 proximamente en http://www.who.int/medicines/publications/newsletter/en/
Etiquetas:
bifosfonatos,
calcitonina,
candesartán,
dabigatrán,
dalfampridine,
Denosumab,
doripenem,
estatinas,
febuxostat,
mometasona,
OMS,
Signal,
tacrolimus,
tolperisona,
trimetazidina,
Uppsala Monitoring Centre,
zolpidem
No hay comentarios:
Publicar un comentario